Literature DB >> 28898618

[Klebsiella pneumoniae from K1 and Hypervirulent Clone ST23: First Documented Case in Portugal].

Aida Pereira1, Tiago Petrucci2, Maria João Simões3.   

Abstract

The hypervirulent K1 serotype Klebsiella pneumoniae is responsible for a new invasive syndrome, typically associated to hepatic abscesses with extra-hepatic complications. Initially described in Taiwan, it has significantly spread to several Asian countries and more recently to Europe and North America, thus constituting an emerging and global problem. The authors describe a case report of a 64-years-old portuguese caucasian woman without any previous diseases or epidemiological risk factors such as trips or contact with Asian products or population, diagnosed with a pyogenic liver abscess with pleural effusion caused by this hyper-virulent strain. A successful clinical cure was achieved after the etiological identification and treatment with antimicrobial therapy combined with catheter drainage. This is the first identification of hypervirulent Klebsiella pneumonia ST 23 clone in Portugal in the context of an invasive syndrome.

Entities:  

Keywords:  Klebsiella Infections; Klebsiella pneumonia; Liver Abscess; Portugal

Mesh:

Year:  2017        PMID: 28898618     DOI: 10.20344/amp.7705

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  2 in total

1.  Evidence of Sharing of Klebsiella pneumoniae Strains between Healthy Companion Animals and Cohabiting Humans.

Authors:  Cátia Marques; Adriana Belas; Catarina Aboim; Patrícia Cavaco-Silva; Graça Trigueiro; Luís Telo Gama; Constança Pomba
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

2.  Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil.

Authors:  Rafael Nakamura-Silva; Louise Cerdeira; Mariana Oliveira-Silva; Karen Regina Carim da Costa; Elder Sano; Bruna Fuga; Quézia Moura; Fernanda Esposito; Nilton Lincopan; Kelly Wyres; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2022-03-04       Impact factor: 2.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.